Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Esperovax Awarded $1.5 Million Subcontract for Development of Thermostable Oral H5N1 Influenza RNA Vaccine
Dec 12, 2024•over 1 year ago
Contract Type
contract
PlymouthBiotechnologyDescription
Esperovax, Inc. has been awarded a two-year base subcontract valued at $1.5 million by DynPort Vaccine Company LLC for the pre-clinical development of an oral H5N1 influenza RNA vaccine. This subcontract is part of the U.S. Department of Defense's Defense Threat Reduction Agency Medical CBRN Defense Consortium's Other Transactional Agreement and aims to address significant storage, shelf-life, manufacturing expense, and duration of immunity challenges.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months